Cholesterol management in the era of managed care

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Several large controlled clinical trials have documented that cholesterol lowering causes a marked reduction in major coronary events in patients with established coronary heart disease. Cholesterol lowering thus joins other proven therapies for risk reduction in secondary prevention. The need to include cholesterol-lowering therapy in secondary prevention has been endorsed as a new practice measure in the Health Plan Employer Data Information Set. This endorsement ensures that managed care will get behind the effort to better control cholesterol in patients with coronary heart disease. The next issue is whether managed care will support cholesterol-lowering therapy in primary-prevention patients. The patients at highest risk for developing coronary heart disease are those with noncoronary forms of atherosclerotic disease, type 2 diabetes, multiple risk factors, and risk factors plus evidence of advanced subclinical atherosclerosis. Such patients can be said to have coronary heart disease risk equivalents. These patients should be good candidates for aggressive cholesterol management. A strong case can be made for managed-care support for this approach. Support for treatment of patients at lower risk may be open to some question, but the current guidelines of the National Cholesterol Education Program provide a strong rationale for cholesterol management for primary prevention in the medical setting. Copyright (C) 2000 Excerpta Medica Inc.

Original languageEnglish (US)
Pages (from-to)3-9
Number of pages7
JournalAmerican Journal of Cardiology
Volume85
Issue number3 SUPPL. 1
DOIs
StatePublished - Feb 10 2000

Fingerprint

Managed Care Programs
Cholesterol
Coronary Disease
Primary Prevention
Secondary Prevention
Controlled Clinical Trials
Risk Reduction Behavior
Therapeutics
Type 2 Diabetes Mellitus
Atherosclerosis
Guidelines
Education
Health

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cholesterol management in the era of managed care. / Grundy, Scott M.

In: American Journal of Cardiology, Vol. 85, No. 3 SUPPL. 1, 10.02.2000, p. 3-9.

Research output: Contribution to journalArticle

@article{e4f15244290949f1bee49f71d186fc0f,
title = "Cholesterol management in the era of managed care",
abstract = "Several large controlled clinical trials have documented that cholesterol lowering causes a marked reduction in major coronary events in patients with established coronary heart disease. Cholesterol lowering thus joins other proven therapies for risk reduction in secondary prevention. The need to include cholesterol-lowering therapy in secondary prevention has been endorsed as a new practice measure in the Health Plan Employer Data Information Set. This endorsement ensures that managed care will get behind the effort to better control cholesterol in patients with coronary heart disease. The next issue is whether managed care will support cholesterol-lowering therapy in primary-prevention patients. The patients at highest risk for developing coronary heart disease are those with noncoronary forms of atherosclerotic disease, type 2 diabetes, multiple risk factors, and risk factors plus evidence of advanced subclinical atherosclerosis. Such patients can be said to have coronary heart disease risk equivalents. These patients should be good candidates for aggressive cholesterol management. A strong case can be made for managed-care support for this approach. Support for treatment of patients at lower risk may be open to some question, but the current guidelines of the National Cholesterol Education Program provide a strong rationale for cholesterol management for primary prevention in the medical setting. Copyright (C) 2000 Excerpta Medica Inc.",
author = "Grundy, {Scott M}",
year = "2000",
month = "2",
day = "10",
doi = "10.1016/S0002-9149(99)00932-7",
language = "English (US)",
volume = "85",
pages = "3--9",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3 SUPPL. 1",

}

TY - JOUR

T1 - Cholesterol management in the era of managed care

AU - Grundy, Scott M

PY - 2000/2/10

Y1 - 2000/2/10

N2 - Several large controlled clinical trials have documented that cholesterol lowering causes a marked reduction in major coronary events in patients with established coronary heart disease. Cholesterol lowering thus joins other proven therapies for risk reduction in secondary prevention. The need to include cholesterol-lowering therapy in secondary prevention has been endorsed as a new practice measure in the Health Plan Employer Data Information Set. This endorsement ensures that managed care will get behind the effort to better control cholesterol in patients with coronary heart disease. The next issue is whether managed care will support cholesterol-lowering therapy in primary-prevention patients. The patients at highest risk for developing coronary heart disease are those with noncoronary forms of atherosclerotic disease, type 2 diabetes, multiple risk factors, and risk factors plus evidence of advanced subclinical atherosclerosis. Such patients can be said to have coronary heart disease risk equivalents. These patients should be good candidates for aggressive cholesterol management. A strong case can be made for managed-care support for this approach. Support for treatment of patients at lower risk may be open to some question, but the current guidelines of the National Cholesterol Education Program provide a strong rationale for cholesterol management for primary prevention in the medical setting. Copyright (C) 2000 Excerpta Medica Inc.

AB - Several large controlled clinical trials have documented that cholesterol lowering causes a marked reduction in major coronary events in patients with established coronary heart disease. Cholesterol lowering thus joins other proven therapies for risk reduction in secondary prevention. The need to include cholesterol-lowering therapy in secondary prevention has been endorsed as a new practice measure in the Health Plan Employer Data Information Set. This endorsement ensures that managed care will get behind the effort to better control cholesterol in patients with coronary heart disease. The next issue is whether managed care will support cholesterol-lowering therapy in primary-prevention patients. The patients at highest risk for developing coronary heart disease are those with noncoronary forms of atherosclerotic disease, type 2 diabetes, multiple risk factors, and risk factors plus evidence of advanced subclinical atherosclerosis. Such patients can be said to have coronary heart disease risk equivalents. These patients should be good candidates for aggressive cholesterol management. A strong case can be made for managed-care support for this approach. Support for treatment of patients at lower risk may be open to some question, but the current guidelines of the National Cholesterol Education Program provide a strong rationale for cholesterol management for primary prevention in the medical setting. Copyright (C) 2000 Excerpta Medica Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033973897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033973897&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(99)00932-7

DO - 10.1016/S0002-9149(99)00932-7

M3 - Article

VL - 85

SP - 3

EP - 9

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3 SUPPL. 1

ER -